Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Background: Pracinostat is a potent oral inhibitor of histone deacetylases (HDAC’s), selective for class I, II and IV isoforms. In-vitro cytotoxicity assays in AML cell lines revealed an IC50 of

Saved in:
Bibliographic Details
Published in:Blood 2014-12, Vol.124 (21), p.947-947
Main Authors: Garcia-Manero, Guillermo, Atallah, Ehab, Odenike, Olatoyosi, Medeiros, Bruno C, Cortes, Jorge E., Esquibel, Vanessa, Cha, Steven, Khaled, Samer K
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Pracinostat is a potent oral inhibitor of histone deacetylases (HDAC’s), selective for class I, II and IV isoforms. In-vitro cytotoxicity assays in AML cell lines revealed an IC50 of
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V124.21.947.947